Chest Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text Free
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Robbins, R. A.
Right arrow Articles by Hayden, J. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Robbins, R. A.
Right arrow Articles by Hayden, J. M.
(Chest. 2005;128:4036-4040.)
© 2005 American College of Chest Physicians

Heat Decreases Formoterol Delivery*

Richard A. Robbins, MD; Allen R. Thomas, MD; Lynda M. Proctor, PharmD; Jeffrey C. Hoyt, PhD and John M. Hayden, PhD

* From Pulmonary and Critical Care Medicine, Pharmacy Department, and Research Service, Carl T. Hayden Veterans Affairs Medical Center, Phoenix, AZ.

Correspondence to: Richard A. Robbins, MD, Pulmonary and Critical Care Medicine, Carl T. Hayden VA Medical Center, 650 East Indian School Rd, Phoenix, AZ 85012; e-mail: Richard.Robbins2{at}med.va.gov

Study objectives: Based on anecdotal reports of formoterol aggregating in mailboxes in the summer in Arizona, we examined the effect of heat on formoterol as well as on drug delivery.

Design: Formoterol capsules in original blister packaging were heated to 40 to 70°C (104 to 158°F) for 3 h and at 70°C (158°F) for 15 to 180 min. Capsules were removed from packaging, and a vacuum setup was used to dispense the formoterol into a filter using the device provided by the manufacturer. The weights of the capsule predispensation and postdispensation were measured to calculate drug delivery. Measurements were compared to those of capsules not exposed to heat. For comparison, tiotropium and a combination of fluticasone propionate and salmeterol (Advair; GlaxoSmithKline; Research Triangle Park, NC) were similarly tested.

Results: Visual inspection of the heated capsules revealed gross distortion as well as visible clumping of formoterol at the higher temperatures. The mean (± SEM) change in the weights of capsules that underwent heating were significantly less than those obtained from capsules that had not been heated (mean change after heating for 3 h at 70°C, 2.3 ± 0.7 vs 24.7 ± 0.6 mg, respectively; p < 0.001), indicating decreased formoterol delivery. Heat produced a dose-responsive and time-responsive decrease in formoterol delivery. One of six capsules that were subjected to temperatures as low as 40°C (104°F) for 3 h had decreased delivery, and three of six capsules subjected to a temperature of 70°C (158°F) for times as short as 30 min decreased delivery. In contrast, neither tiotropium nor fluticasone propionate/salmeterol delivery was decreased by heating for up to 3 h at 70°C (158°F). Thermometers placed in mailboxes or in car windows in mid-summer in Arizona (approximate outside temperature, 110°F [43°C]) exceeded 70°C (158°F).

Conclusions: These data demonstrate that the exposure of formoterol to heat decreases drug delivery and that caution should be used when mailing, transporting or storing formoterol.

Key Words: bronchodilator • capsule • drug delivery • formoterol • heat • powder






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by the American College of Chest Physicians.